

# Sequencing of Agents and Combination Of Treatment for Metastatic RCC

- Neo-adjuvant medications for downsizing kidney cancer occasionally work, and more trials are in progress.
- Only 1 adjuvant medication, Sunitinib, has been FDA approved, and does not prolong overall survival, only disease free survival.
- For metastatic disease, there are 4 frontline dual medication approvals which are either dual immuno-oncology agents, or a tyrosine kinase and immuno-oncology agents.

